Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Leukemia 2Lymphoma, T-Cell 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 52Vincristine 32blinatumomab 30Prednisone 27Methotrexate 27Cytarabine 25Dexamethasone 23Specimen Handling 21Rituximab 20Doxorubicin 19merphos 18Mercaptopurine 18Etoposide 18fludarabine 17Biopsy 17prednylidene 16deltacortene 16N,N-dicyclohexyl-isoborneol-10-sulfonamide 16Calcium Dobesilate 16dexamethasone acetate 15dexamethasone 21-phosphate 15auricularum 15Inotuzumab Ozogamicin 15pegaspargase 14azathiopurine 14venetoclax 13Asparaginase 13Spinal Puncture 12Leucovorin 12CT-P10 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × nelarabine × 1 year × Clear all
NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
53 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡